The Gulf States Hemophilia and Thrombophilia Center’s (GSHTC) Research Program affiliated with The University of Texas Health Science Center at Houston is involved in the forefront of clinical research studies evaluating: individualizing prophylaxis for the prevention of bleeding, non-factor therapies, gene therapy and risk factors associated with inhibitor development for the care of people with coagulation disorders. In addition to conducting industry sponsored clinical trials, we are affiliated with the American Thrombosis and Hemostasis Network (ATHN) a nonprofit organization dedicated to improving the lives of people affected by bleeding and clotting disorders. Collaborative research endeavors with ATHN and other hemophilia centers throughout the United States have led to the collection of information to monitor trends, identify risks factors and rates of complications within the bleeding disorders community. We are committed to shortening the transition from basic research findings into scientific clinical trials that will assist persons with bleeding disorders. These research endeavors have provided patients with access to new methods of treatment that demonstrated the clinical efficacy and safety of new clotting factor products and non-factor therapy; treatment for inhibitors; and people with hemophilia who received gene therapy will possibly produce higher levels of FVIII or FIX. Many patients participating in clinical research trials receive treatment for their bleeding disorder, medical, laboratory and radiological evaluations at no cost to the patient or private third party payers, during the conduct of the study. For more information, contact GSHTC at 713-500-8360.